The global metagenomic sequencing market is undergoing a significant transformation fueled by advances in genomics, increasing infectious disease prevalence, and rising applications in precision medicine and biotechnology. In 2024, the market was valued at USD 2.24 billion, reaching USD 2.53 billion in 2025, and is forecasted to hit approximately USD 7.63 billion by 2034, growing at a CAGR of 13.04% from 2025 to 2034.

Metagenomic sequencing enables the comprehensive analysis of microbial communities in various environments without the need for culturing. Applications in agriculture, diagnostics, drug discovery, and environmental monitoring continue to drive demand.

Key Market Highlights

• Market Size: USD 2.24 billion in 2024

• Forecast: USD 7.63 billion by 2034

• CAGR: 13.04% (2025–2034)

• Dominant Region (2024): North America

• Fastest-Growing Region: Asia-Pacific

• Leading Sequencing Approach: Whole Genome Shotgun (WGS)

---

Top Companies in the Metagenomic Sequencing Market

1. Illumina, Inc.

• About: A leader in DNA sequencing and array-based technologies, Illumina empowers research in genomics and molecular diagnostics.

• Key Products: NovaSeq, MiSeq, NextSeq series

• Market Cap: ~$19 billion (as of mid-2025)

2. Thermo Fisher Scientific

• About: A global science services company providing innovative technologies across analytical instruments, life sciences, and diagnostics.

• Key Products: Ion Torrent, Oncomine assays

• Market Cap: ~$200 billion

3. Oxford Nanopore Technologies

• About: Renowned for its real-time, portable nanopore sequencing, used for metagenomics in field and lab settings.

• Key Products: MinION, PromethION, GridION

• Market Cap: ~$2.8 billion

4. Pacific Biosciences (PacBio)

• About: Known for high-accuracy long-read sequencing platforms that are ideal for complex genome and microbiome studies.

• Key Products: Revio, Sequel IIe

• Market Cap: ~$1.2 billion

5. Qiagen

• About: Provides sample and assay technologies for molecular diagnostics, academic research, and pharma R&D.

• Key Products: QIAseq kits, bioinformatics pipelines

• Market Cap: ~$9 billion

6. BGI Genomics

• About: China-based genomics company offering sequencing services and solutions globally.

• Key Products: DNBSEQ platforms

• Market Cap: ~$5.5 billion

7. Novogene

• About: A leading provider of next-generation sequencing and bioinformatics services with a focus on scientific research and clinical diagnostics.

• Key Products: Whole-genome, 16S/18S rRNA, metagenomic sequencing

• Market Cap: Private company (valuation undisclosed)

8. Zymo Research

• About: Specializes in DNA/RNA purification, microbiome analysis, and epigenetics tools.

• Key Products: ZymoBIOMICS, DNA/RNA kits

• Market Cap: Private company

9. CosmosID

• About: Provides metagenomic analysis solutions for healthcare, agriculture, and environmental applications.

• Key Products: CosmosID-HUB platform

• Market Cap: Private company

10. IDbyDNA

• About: A pioneer in metagenomic infectious disease diagnostics and pathogen detection.

• Key Products: Explify Platform

• Market Cap: Acquired by Illumina

11. Adaptive Biotechnologies

• About: Focuses on immune-driven diagnostics and therapeutics, particularly for infectious diseases and cancer.

• Key Products: immunoSEQ, clonoSEQ

• Market Cap: ~$1 billion

12. Diversigen (Part of GSK)

• About: Offers microbiome sequencing services for clinical trials and research; acquired by GSK to expand its microbiome R&D capabilities.

• Key Products: DNA/RNA extraction and metagenomic sequencing

• Market Cap: Integrated under GSK (GSK Market Cap ~$100 billion)

13. BiomeSense

• About: Develops continuous microbiome monitoring hardware and data analytics solutions.

• Key Products: Automated microbiome samplers

• Market Cap: Private startup

14. Helix

• About: A population genomics company providing DNA testing, analytics, and population health solutions.

• Key Products: Helix COVID-19 sequencing, Exome+

• Market Cap: Private company

15. Microbiome Insights

• About: Offers contract research services for microbiome research across human, animal, and environmental sectors.

• Key Products: 16S rRNA gene sequencing, metagenomics, metabolomics

• Market Cap: Private company

16. GeneWiz (Azenta Life Sciences)

• About: Provides genomics services including Sanger sequencing, NGS, and bioinformatics. Acquired by Azenta.

• Key Products: NGS, Sanger, gene synthesis

• Market Cap: Azenta Life Sciences ~$3.2 billion

17. Novartis Institutes for BioMedical Research (NIBR)

• About: The R&D arm of Novartis focused on pioneering therapies using genomic and cellular tools.

• Key Products: Internal research platforms, clinical collaborations

• Market Cap: Novartis ~$240 billion

---

Future Outlook

The metagenomic sequencing market is expected to thrive with growing investments in precision medicine, bioinformatics, and biopharmaceutical innovation. Regions like Asia-Pacific are poised to witness the fastest growth due to increasing healthcare infrastructure, favorable government initiatives, and expanding biotech R&D.

Request a customized case study tailored to your business needs and gain deeper insights
into healthcare market strategies: sales@towardshealthcare.com

---

Frequently Asked Questions (FAQs)

1. What is metagenomic sequencing used for?

Metagenomic sequencing is used for analyzing microbial communities in various environments, enabling diagnostics, drug discovery, agricultural research, and environmental studies.

2. Which region leads the metagenomic sequencing market?

North America held the largest market share in 2024, due to technological advancements and high research funding.

3. What is the most popular sequencing approach in the market?

Whole-genome shotgun (WGS) sequencing dominated the market in 2024 because of its accuracy and depth in metagenomic analysis.

4. Which companies are leading in this market?

Major players include Illumina, Thermo Fisher Scientific, Oxford Nanopore Technologies, PacBio, and Qiagen.

5. What is the expected market size by 2034?

The global metagenomic sequencing market is projected to reach approximately USD 7.63 billion by 2034.

Source : https://www.towardshealthcare.com/insights/metagenomic-sequencing-market-sizing

Invest in Our Premium Strategic Solution: https://www.towardshealthcare.com/price/5887